





Ritonavir: Treating HIV/AIDS



Ritonavir is an antiretroviral drug mainly used as a protease inhibitor in combination therapies treating HIV/AIDS.


Patenting activity

Number of patent families* (reduction after 2006 may be attributed to publication lag, market maturity or economic recession)



Top 10 applicants

Number of patent families



The initial patent for Ritonavir was filed in 1993 by Abbott Laboratories.

805


Total number of patent families

45%

of patent families received at least one granted patent


Top 10 origins

Number of patent filings per office of first filing



Geographic distribution of extensions

% of patent families having a subsequent filing with further offices



Selected innovation tracks

What does the patent landscape indicate in areas important for developing countries interested in domestic generic manufacturing?

- Synthesis** Well protected by large companies; limited potential for additional innovation
- Liquid dosage forms** Increasingly narrower formulations through patent generations
- Solid dosage forms** Potential for further innovation suggested by low number of filings
- Crystalline Ritonavir and polymorphs** Recent protection of formulations with specific forms
- Prodrugs** Emergent area of patenting activity